An impermeant ganetespib analog inhibits extracellular Hsp90-mediated cancer cell migration that involves Lysyl oxidase 2-like protein

Cancers

Volumn 6, Issue 2, 2014, Pages 1031-1046

  Mccready, Jessica ^a   Wong, Daniel S ^b,c   Burlison, Joseph A ^d   Ying, Weiwen ^d   Jay, Daniel G ^b,c  

^a ASSUMPTION COLLEGE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TUFTS UNIVERSITY   (United States)

^d Synta Pharmaceuticals Corp   (United States)

Author keywords

Cancer cell migration; Extracellular Hsp90; Ganetespib; Lysyl oxidase 2 like protein

Indexed keywords

CYTOTOXIC AGENT; GALECTIN 3 BINDING PROTEIN; GANETESPIB; HEAT SHOCK PROTEIN 90; LYSYL OXIDASE 2 LIKE PROTEIN; PROTEIN PRECURSOR; STA 12 7191; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG STRUCTURE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MASS SPECTROMETRY; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION;

EID: 84901189858     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6021031     Document Type: Article

References (40)

1. Wells, A.; Grahovac, J.; Wheeler, S.; Ma, B.; Lauffenburger, D. Targeting tumor cell motility as a strategy against invasion and metastasis. Trends Pharmacol. Sci. 2013, 34, 283-289.
2. Eustace, B.K.; Sakurai, T.; Stewart, J.K.; Yimlamai, D.; Unger, C.; Zehetmeier, C.; Lain, B.; Torella, C.; Henning, S.W.; Beste, G. et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat. Cell Biol. 2004, 6, 507-514.
3. Sloan, K.E.; Stewart, J.K.; Treloar, A.F.; Matthews, R.T.; Jay, D.G. CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics. Cancer Res. 2005, 65, 10930-10937.
4. Bagci, T.; Wu, J.K.; Pfannl, R.; Ilag, L.L.; Jay, D.G. Autocrine semaphoring 3A signaling promotes glioblastoma dispersal. Oncogene 2009, 28, 3537-3550.
5. Hong, D.S.; Banerji, U.; Tavana, B.; George, G.C.; Aaron, J.; Kurzrock, R. Targeting the molecular chaperone heat shock protein 90 (HSP90): Lessons learned and future directions. Cancer Treat. Rev. 2013, 39, 375-387.
6. Barrott, J.J.; Haystead, T.A. Hsp90, an unlikely ally in the war on cancer. FEBS J. 2013, 280, 1381-1396.
7. Picard, D. Hsp90 invades the outside. Nat. Cell Biol. 2004, 6, 479-480.
8. Li, W.; Sahu, D.; Tsen, F. Secreted heat shock protein-90 (Hsp90) in wound healing and cancer. Biochim. Biophys. Acta 2012, 1823, 730-741.
9. Sidera, K.; Gaitanou, M.; Stellas, D.; Matsas, R.; Patsavoudi, E. A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. J. Biol. Chem. 2008, 283, 2031-2041.
10. McCready, J.; Sims, J.D.; Chan, D.; Jay, D.G. Secretion of extracellular hsp90alpha via exosomes increases cancer cell motility: A role for plasminogen activation. BMC Cancer 2010, 10, 294.
11. Chen, J.S.; Hsu, Y.S.M.; Chen, C.C.; Lee, C.C.; Huang, T.S. Secreted Heat Shock Protein alpha Induces Colorectal Cancer Cell Invasion through CD91/LRP-1 and NFkB-mediated Integrin alpha v expression. J. Biol. Chem. 2010, 285, 25458-2566.
12. Gopal, U.; Bohonowych, J.E.; Lema-Tome, C.; Liu, A.; Garrett-Mayer, E.; Wang, B.; Isaacs, J.S. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. PLoS One 2011, 6, e17649.
13. Hance, M.W.; Dole, K.; Gopal, U.; Bohonowych, J.E.; Jezierska-Drutel, A.; Neumann, C.A.; Liu, H.; Garraway, I.P.; Isaacs, J.S. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. J. Biol. Chem. 2012, 287, 37732-37744.
14. Stellas, D.; el Hamidieh, A.; Patsavoudi, E. Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biol. 2010, 11, doi:10.1186/1471-2121-11-51.
15. Woodley, D.T.; Fan, J.; Cheng, C.F.; Li, Y.; Chen, M.; Bu, G.; Li, W. Participation of the lipoprotein receptor LRP1 in hypoxia-HSP90alpha autocrine signaling to promote keratinocyte migration. J. Cell Sci. 2009, 122, 1495-1498.
16. Acquaviva, J.; Smith, D.L.; Sang, J.; Friedland, J.C.; He, S.; Sequeira, M.; Zhang, C.; Wada, Y.; Proia, D.A. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol. Cancer Ther. 2012, 11, 2633-2643.
17. Ying, W.; Du, Z.; Sun, L.; Foley, K.P.; Proia, D.A.; Blackman, R.K.; Zhou, D.; Inoue, T.; Tatsuta, N.; Sang, J. et.al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol. Cancer Ther. 2012, 11, 475-478.
18. Woo, H.J.; Shaw, L.M.; Messier, J.M.; Mercurio, A.M. The major non-integrin laminin binding protein of macrophages is identical to carbohydrate binding protein 35 (Mac-2). J. Biol. Chem. 1990, 265, 7097-7099.
19. Koths, K.; Taylor, E.; Halenbeck, R.; Casipit, C.; Wang, A. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J. Biol. Chem. 1993, 268, 14245-14249.
20. Iacobelli, S.; Sismondi, P.; Giai, M.; D'Egidio, M.; Tinari, N.; Amatetti, C.; di Stefano, P.; Natoli, C. Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br. J. Cancer 1994, 69, 172-176.
21. Whelan, S.A.; He, J.; Lu, M.; Souda, P.; Saxton, R.E.; Faull, K.F.; Whitelegge, J.P.; Chang, H.R. Mass spectrometry (LC-MS/MS) identified proteomic biosignatures of breast cancer in proximal fluid. J. Proteome Res. 2012, 11, 5034-5045.
22. Kim, Y.S.; Jung, J.A.; Kim, H.J.; Ahn, Y.H.; Yoo, J.S.; Oh, S.; Cho, C.; Yoo, H.S.; Ko, J.H. Galectin-3 binding protein promotes cell motility in colon cancer by stimulating the shedding of protein tyrosine phosphatase kappa by proprotein convertase 5. Biochem. Biophys. Res. Commun. 2011, 404, 96-102.
23. Marchetti, A.; Tinari, N.; Buttitta, F.; Chella, A.; Angeletti, C.A.; Sacco, R.; Mucilli, F.; Ullrich, A.; Iacobelli, S. Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res. 2002, 62, 2535-2539.
24. Moreno-Bueno, G.; Salvador, F.; Martín, A.; Floristán, A.; Cuevas, E.P.; Santos, V.; Montes, A.; Morales, S.; Castilla, M.A.; Rojo-Sebastián, A.; et al. Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. EMBO Mol. Med. 2011, 3, 528-544.
25. Akiri, G.; Sabo, E.; Dafni, H.; Vadasz, Z.; Kartvelishvily, Y.; Gan, N.; Kessler, O.; Cohen, T.; Resnick, M.; Neeman, M. et al. Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo. Cancer Res. 2003, 63, 1657-1666.
26. Peinado, H.; del Carmen Iglesias C. M.; Olmeda, D.; Csiszar, K.; Fong, K.S.; Vega, S.; Nieto, M.A.; Cano, A.; Portillo, F. A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. EMBO J. 2005, 24, 3446-3458.
27. Barker, H.E.; Chang, J.; Cox, T.R.; Lang, G.; Bird, D.; Nicolau, M.; Evans, H.R.; Gartland, A.; Erler, J.T. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Cancer Res. 2011, 71, 1561-1572.
28. Inohara, H.; Akahani, S.; Koths, K.; Raz, A. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res. 1996, 56, 4530-4534.
29. Ulmer, T.A.; Keeler, V.; André, S.; Gabius, H.J.; Loh, L.; Laferté, S. The tumor-associated antigen 90K/Mac-2-binding protein secreted by human colon carcinoma cells enhances extracellular levels of promatrilysin and is a novel substrate of matrix metalloproteinases-2, -7 (matrilysin) and -9: Implications of proteolytic cleavage. Biochim. Biophys. Acta 2010, 1800, 336-343.
30. Wang, X.; Song, X.; Zhuo, W.; Fu, Y.; Shi, H.; Liang, Y.; Tong, M.; Chang, G.; Luo, Y. The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy. Proc. Natl. Acad. Sci. USA 2009, 106, 21288-21293.
31. Tsutsumi, S.; Scroggins, B.; Koga, F.; Lee, M.J.; Trepel, J.; Felts, S.; Carreras, C.; Neckers, L. A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene 2008, 27, 2478-2487.
32. Kummar, S.; Gutierrez, M.E.; Gardner, E.R.; Chen, X.; Figg, W.D.; Zajac-Kaye, M.; Chen, M.; Steinberg, S.M.; Muir, C.A.; Yancey, M.A. et al. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur. J. Cancer 2010, 46, 340-347.
33. Barrott, J.J.; Hughes, P.F.; Osada, T.; Yang, X.Y.; Hartman, Z.C.; Loiselle, D.R.; Spector, N.L.; Neckers, L.; Rajaram, N.; Hu, F. et al. Optical and radioiodinated tethered hsp90 inhibitors reveal selective internalization of ectopic hsp90 in malignant breast tumor cells. Chem. Biol. 2013, 20, 1187-1197.
34. Shimamura, T.; Perera, S.A.; Foley, K.P.; Sang, J.; Rodig, S.J.; Inoue, T.; Chen, L.; Li, D.; Carretero, J.; Li, Y.C. et al. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin. Cancer Res. 2012, 18, 4973-4985.
35. Chen, J.; Lu, L.; Feng, Y.; Wang, H.; Dai, L.; Li, Y.; Zhang, P. PKD2 mediates multi-drug resistance in breast cancer cells through modulation of P-glycoprotein expression. Cancer Lett. 2011, 300, 48-56.
36. Sims, J.D.; McCready, J.; Jay, D.G. Extracellular heat shock protein (hsp)70 and hsp90a assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion. PLoS One 2011, 6, e18848.
37. Daquinag, A.; Fadri, M.; Jung, S.Y.; Qin, J.; Kunz, J. The yeast PH domain proteins Slm1 and Slm2 are targets of sphingolipid signaling during the response to heat stress. Mol. Cell. Biol. 2007, 27, 633-650.
38. Ritz, C.; Streigbig, J.C. Bioassay analysis using R. J. Stat. Softw. 2005, 12, 1-22.
39. Barry-Hamilton, V.; Spangler, R.; Marshall, D.; McCauley, S.; Rodriguez, H.M.; Oyasu, M.; Mikels, A.; Vaysberg, M.; Ghermazien, H.; Wai, C. et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat. Med. 2010, 16, 1009-1017.
40. Peng, L.; Ran, Y.L.; Hu, H.; Yu, L.; Liu, Q.; Zhou, Z.; Sun, Y.M.; Sun, L.C.; Pan, J.; Sun, L.X. et al. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway. Carcinogenesis 2009, 30, 1660-1669.